Research programme: companion diagnostic tests - Abbott/GlaxoSmithKline

Drug Profile

Research programme: companion diagnostic tests - Abbott/GlaxoSmithKline

Latest Information Update: 30 Nov 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; GlaxoSmithKline Biologicals
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 30 Nov 2011 MAGE-A3 diagnostic test is still in preclinical trials for diagnosis of Malignant melanoma and Non-small cell lung cancer in USA
  • 29 Nov 2011 Abbott expands its agreement with GlaxoSmithKline to include another companion diagnostic test for the PRAME antigen
  • 03 Mar 2010 Preclinical trials in Malignant melanoma (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top